Edotreotide
Digestive System Neuroendocrine Neoplasm
Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Modality
protein_peptide
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06091748CT.gov Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors | — | Completed | — | — | — |
NCT04915144CT.gov 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Digestive System Neuroendocrine Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Edotreotide (this asset) | Jiangsu HengRui Medicine Co., Ltd. | P3 | B · 63 |
| Oxodotreotide | National Cancer Institute (NCI) | P4 | BBB |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | Novartis Pharmaceuticals | P3 | BB |
| Eudemine Injection | University of Maryland, Baltimore | P4 | BB |
| Everolimus | RayzeBio, Inc. | P3 | BB |
| Lanreotide | RayzeBio, Inc. | P3 | B |
| Regorafenib | Translational Research in Oncology | P2 | B |
| Pasireotide | University of Maryland, Baltimore | P4 | B |
| Lanreotide Autogel | Ipsen | P2 | B |
+23 more in the Digestive System Neuroendocrine Neoplasm cohort
Other indications for Edotreotide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neuroblastoma | — | P2 | B · 60 |
| Carcinoid Tumor | — | P2 | B · 59 |
| Pancreatic Neuroendocrine Tumor | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Edotreotide in Digestive System Neuroendocrine Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/edotreotide-digestive-system-neuroendocrine-neoplasm-124605
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →